Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

裕利医药，亚洲领先的医疗保健解决方案公司，今天宣布已从拜耳消费者护理有限公司收购了Zam-Buk®和Vapex®消费者保健品牌在泰国、新加坡、印度尼西亚、马来西亚和文莱的所有权利、所有权和利益。

Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion.

Zam-Buk® 是一种用于暂时缓解疼痛和瘙痒的软膏，包括昆虫叮咬引起的不适。自1902年首次推出以来，Zam-Buk® 在几十年间一直保持着强大的品牌价值，被广泛认为是值得信赖的家庭品牌。Vapex® 是一种用于帮助缓解鼻塞的鼻腔吸入器。

Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand..

自1917年推出以来，Vapex®建立了有意义的品牌认知度，尤其是在泰国。

The acquisition of the brands supports Zuellig Pharma's strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company's second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region..

这些品牌的收购支持了裕利医药加强并扩大其在亚洲的消费者健康产品组合的战略重点。这也是该公司继菲律宾的Propan之后的第二次消费者健康产品收购，进一步巩固了其在该地区建立一个强大的、值得信赖的日常健康产品商业平台的关注点。

'This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk® and Vapex® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands' legacy with Zuellig Pharma's regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region.

“此次收购标志着我们的消费者医疗保健产品组合又一个重要的增长里程碑。Zam-Buk® 和 Vapex® 是具有深厚传统和社区信任的持久品牌。通过将这些品牌的传统与裕利医药的区域商业能力和本地市场专业知识相结合，我们旨在扩大在整个地区所有相关零售渠道的分销和覆盖。”

In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers.' said John Graham, CEO of Zuellig Pharma..

约翰·格雷厄姆表示：“通过这样做，这些品牌将继续保持与消费者的关联性、易于查找并且方便获取。”

About Zuellig Pharma

关于裕利医药科技股份有限公司

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region.

裕利医药是亚洲领先的医疗保健解决方案公司，我们的宗旨是让所服务的社区更容易获得医疗保健。我们提供世界级的分销、商业化和临床试验支持服务，依托强大的创新文化，满足该地区不断增长的医疗保健需求。

The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world..

公司成立于一百年前，现已成长为一家覆盖18个市场、拥有超过12,000名员工的数十亿美元企业。我们的团队为超过20万家医疗机构提供服务，并与450多家客户合作，其中包括全球前20大制药公司。

The issuer is solely responsible for the content of this announcement.

发行人对本公告的内容负全责。

Media Contact(s)

媒体联系人

Angelene Chong

钟安洁

Head of Corporate Communications

企业传播主管

achongam@zuelligpharma.com

achongam@zuelligpharma.com